Published in Drug Alcohol Depend on February 01, 2002
Managing psychiatric comorbidity within versus outside of methadone treatment settings: a randomized and controlled evaluation. Addiction (2013) 1.59
A meta-analysis of retention in methadone maintenance by dose and dosing strategy. Am J Drug Alcohol Abuse (2009) 1.49
Why we object to NAOMI. Heroin maintenance in Canada. Can Fam Physician (2006) 1.43
Misuse of and dependence on opioids: study of chronic pain patients. Can Fam Physician (2006) 1.40
Structural-level factors affecting implementation of the methadone maintenance therapy program in China. J Subst Abuse Treat (2009) 1.31
Correlates of methadone client retention: a prospective cohort study in Guizhou province, China. Int J Drug Policy (2008) 1.16
Contribution of cytochrome P450 and ABCB1 genetic variability on methadone pharmacokinetics, dose requirements, and response. PLoS One (2011) 1.08
Better retention of Malaysian opiate dependents treated with high dose methadone in methadone maintenance therapy. Harm Reduct J (2010) 1.03
Contribution of the activities of CYP3A, CYP2D6, CYP1A2 and other potential covariates to the disposition of methadone in patients undergoing methadone maintenance treatment. Br J Clin Pharmacol (2009) 0.98
Antidepressant treatment does not improve buprenorphine retention among opioid-dependent persons. J Subst Abuse Treat (2010) 0.91
Meta-analyses of seven of the National Institute on Drug Abuse's principles of drug addiction treatment. J Subst Abuse Treat (2011) 0.86
Methadone induction in primary care for opioid dependence: a pragmatic randomized trial (ANRS Methaville). PLoS One (2014) 0.86
Baclofen for maintenance treatment of opioid dependence: a randomized double-blind placebo-controlled clinical trial [ISRCTN32121581]. BMC Psychiatry (2003) 0.85
Police bribery and access to methadone maintenance therapy within the context of drug policy reform in Tijuana, Mexico. Drug Alcohol Depend (2015) 0.85
The Future of Opioid Agonist Therapies in Ukraine: A Qualitative Assessment of Multilevel Barriers and Ways Forward to Promote Retention in Treatment. J Subst Abuse Treat (2016) 0.85
Association between methadone dose and concomitant cocaine use in methadone maintenance treatment: a register-based study. Subst Abuse Treat Prev Policy (2014) 0.85
A randomized investigation of methadone doses at or over 100 mg/day, combined with contingency management. Drug Alcohol Depend (2012) 0.84
Moving toward personalized medicine in the methadone maintenance treatment program: a pilot study on the evaluation of treatment responses in Taiwan. Biomed Res Int (2013) 0.84
Impact of co-occurring psychiatric disorders on retention in a methadone maintenance program: an 18-month follow-up study. Int J Environ Res Public Health (2009) 0.84
The nature of methadone diversion in England: a Merseyside case study. Harm Reduct J (2012) 0.83
Medications for substance use disorders. Soc Work Public Health (2013) 0.82
Do placebo response rates from cessation trials inform on strength of addictions? Int J Environ Res Public Health (2012) 0.81
Association of polymorphisms in pharmacogenetic candidate genes (OPRD1, GAL, ABCB1, OPRM1) with opioid dependence in European population: a case-control study. PLoS One (2013) 0.81
Patient and clinician's ratings of improvement in methadone-maintained patients: Differing perspectives? Harm Reduct J (2011) 0.80
Normalizing effect of heroin maintenance treatment on stress-induced brain connectivity. Brain (2014) 0.79
Opioid substitution and antagonist therapy trials exclude the common addiction patient: a systematic review and analysis of eligibility criteria. Trials (2015) 0.77
'Crisis' and 'everyday' initiators: A qualitative study of coercion and agency in the context of methadone maintenance treatment initiation. Drug Alcohol Rev (2016) 0.75
Problem drug use the public health imperative: what some of the literature says. Subst Abuse Treat Prev Policy (2009) 0.75
Hospitalized opioid-dependent patients: Exploring predictors of buprenorphine treatment entry and retention after discharge. Am J Addict (2017) 0.75
Male circumcision, penile human papillomavirus infection, and cervical cancer in female partners. N Engl J Med (2002) 10.80
Genome-wide association scan identifies a colorectal cancer susceptibility locus on 11q23 and replicates risk loci at 8q24 and 18q21. Nat Genet (2008) 6.75
Role of parity and human papillomavirus in cervical cancer: the IARC multicentric case-control study. Lancet (2002) 3.96
Gene expression signature to improve prognosis prediction of stage II and III colorectal cancer. J Clin Oncol (2010) 3.30
Diffuse large B-cell lymphoma subgroups have distinct genetic profiles that influence tumor biology and improve gene-expression-based survival prediction. Blood (2005) 3.12
Identification of Lynch syndrome among patients with colorectal cancer. JAMA (2012) 2.77
The poly(ADP-ribose) polymerase inhibitor niraparib (MK4827) in BRCA mutation carriers and patients with sporadic cancer: a phase 1 dose-escalation trial. Lancet Oncol (2013) 2.72
Time trends incidence of both major histologic types of esophageal carcinomas in selected countries, 1973-1995. Int J Cancer (2002) 2.51
Meta-analysis of new genome-wide association studies of colorectal cancer risk. Hum Genet (2011) 2.35
Genetic variation in 8q24 associated with risk of colorectal cancer. Cancer Biol Ther (2007) 2.32
Association of common polymorphisms in inflammatory genes interleukin (IL)6, IL8, tumor necrosis factor alpha, NFKB1, and peroxisome proliferator-activated receptor gamma with colorectal cancer. Cancer Res (2003) 2.18
A DNA methylation fingerprint of 1628 human samples. Genome Res (2011) 2.16
Chromosomal instability correlates with genome-wide DNA demethylation in human primary colorectal cancers. Cancer Res (2006) 2.15
Tests for gene-environment interaction from case-control data: a novel study of type I error, power and designs. Genet Epidemiol (2008) 2.04
Mephedrone (4-methylmethcathinone; 'meow meow'): chemical, pharmacological and clinical issues. Psychopharmacology (Berl) (2010) 1.94
Maximizing association statistics over genetic models. Genet Epidemiol (2008) 1.93
Cervical coinfection with human papillomavirus (HPV) types and possible implications for the prevention of cervical cancer by HPV vaccines. J Infect Dis (2005) 1.86
Human pharmacology of MDMA: pharmacokinetics, metabolism, and disposition. Ther Drug Monit (2004) 1.78
MRE11 deficiency increases sensitivity to poly(ADP-ribose) polymerase inhibition in microsatellite unstable colorectal cancers. Cancer Res (2011) 1.68
Differential DNA hypermethylation and hypomethylation signatures in colorectal cancer. Hum Mol Genet (2004) 1.60
Colorectal cancer intrinsic subtypes predict chemotherapy benefit, deficient mismatch repair and epithelial-to-mesenchymal transition. Int J Cancer (2013) 1.60
Structural and functional imaging studies in chronic cannabis users: a systematic review of adolescent and adult findings. PLoS One (2013) 1.59
A comprehensive analysis of phase I and phase II metabolism gene polymorphisms and risk of colorectal cancer. Pharmacogenet Genomics (2005) 1.53
Follicular lymphomas with and without translocation t(14;18) differ in gene expression profiles and genetic alterations. Blood (2009) 1.46
Genetic variation in 3-hydroxy-3-methylglutaryl CoA reductase modifies the chemopreventive activity of statins for colorectal cancer. Cancer Prev Res (Phila) (2010) 1.45
[Is it necessary to change the regulation in which drugs are not the objective of the medical research?]. Med Clin (Barc) (2011) 1.45
Hypermethylation-associated Inactivation of the Cellular Retinol-Binding-Protein 1 Gene in Human Cancer. Cancer Res (2002) 1.45
Risk of QTc prolongation in a cohort of opioid-dependent HIV-infected patients on methadone maintenance therapy. Clin Infect Dis (2013) 1.44
Specific secondary genetic alterations in mantle cell lymphoma provide prognostic information independent of the gene expression-based proliferation signature. J Clin Oncol (2007) 1.39
Characteristics of heroin addicts entering methadone maintenance treatment: quality of life and gender. Subst Use Misuse (2004) 1.39
A TP53 polymorphism is associated with increased risk of colorectal cancer and with reduced levels of TP53 mRNA. Oncogene (2004) 1.36
Next-generation sequencing meets genetic diagnostics: development of a comprehensive workflow for the analysis of BRCA1 and BRCA2 genes. Eur J Hum Genet (2012) 1.33
3,4-Methylenedioxymethamphetamine (ecstasy) and alcohol interactions in humans: psychomotor performance, subjective effects, and pharmacokinetics. J Pharmacol Exp Ther (2002) 1.32
Smoking, gender, and ethnicity predict somatic BRAF mutations in colorectal cancer. Cancer Epidemiol Biomarkers Prev (2010) 1.31
Clinical value of prognosis gene expression signatures in colorectal cancer: a systematic review. PLoS One (2012) 1.25
Pathologic predictors of microsatellite instability in colorectal cancer. Am J Surg Pathol (2009) 1.23
Dietary inflammatory index and inflammatory gene interactions in relation to colorectal cancer risk in the Bellvitge colorectal cancer case-control study. Genes Nutr (2014) 1.21
DNA methylation biomarkers for noninvasive diagnosis of colorectal cancer. Cancer Prev Res (Phila) (2013) 1.21
Secondary mutations in BRCA2 associated with clinical resistance to a PARP inhibitor. J Pathol (2013) 1.20
The mid p-value in exact tests for Hardy-Weinberg equilibrium. Stat Appl Genet Mol Biol (2013) 1.20
Accounting for error due to misclassification of exposures in case-control studies of gene-environment interaction. Stat Med (2008) 1.16
Common variation in ISL1 confers genetic susceptibility for human congenital heart disease. PLoS One (2010) 1.15
Identification of new putative susceptibility genes for several psychiatric disorders by association analysis of regulatory and non-synonymous SNPs of 306 genes involved in neurotransmission and neurodevelopment. Am J Med Genet B Neuropsychiatr Genet (2009) 1.14
Promoting innovation and excellence to face the rapid diffusion of novel psychoactive substances in the EU: the outcomes of the ReDNet project. Hum Psychopharmacol (2013) 1.12
Contribution of cytochrome P450 and ABCB1 genetic variability on methadone pharmacokinetics, dose requirements, and response. PLoS One (2011) 1.08
Clinical and nutritional evaluation of phenylketonuric patients on tetrahydrobiopterin monotherapy. Mol Genet Metab (2005) 1.08
Designer drugs on the internet: a phenomenon out-of-control? the emergence of hallucinogenic drug Bromo-Dragonfly. Curr Clin Pharmacol (2011) 1.08
Identifying emerging trends in recreational drug use; outcomes from the Psychonaut Web Mapping Project. Prog Neuropsychopharmacol Biol Psychiatry (2012) 1.05
Five-gene model to predict survival in mantle-cell lymphoma using frozen or formalin-fixed, paraffin-embedded tissue. J Clin Oncol (2008) 1.05
Is there a recreational misuse potential for pregabalin? Analysis of anecdotal online reports in comparison with related gabapentin and clonazepam data. Psychother Psychosom (2011) 1.04
Gene expression differences between colon and rectum tumors. Clin Cancer Res (2011) 1.03
Health impacts of long-term exposure to disinfection by-products in drinking water in Europe: HIWATE. J Water Health (2009) 1.03
Association between habitual dietary flavonoid and lignan intake and colorectal cancer in a Spanish case-control study (the Bellvitge Colorectal Cancer Study). Cancer Causes Control (2012) 1.03
Impact of substance dependence and dual diagnosis on the quality of life of heroin users seeking treatment. Subst Use Misuse (2008) 1.03
Comprehensive copy number variant (CNV) analysis of neuronal pathways genes in psychiatric disorders identifies rare variants within patients. J Psychiatr Res (2010) 1.02
Novel methylation panel for the early detection of colorectal tumors in stool DNA. Clin Colorectal Cancer (2010) 1.02
Creating a transatlantic research enterprise for preventing Alzheimer's disease. Alzheimers Dement (2009) 1.02
Variability in prescription drug expenditures explained by adjusted clinical groups (ACG) case-mix: a cross-sectional study of patient electronic records in primary care. BMC Health Serv Res (2008) 1.01
Determination of MDMA and its metabolites in blood and urine by gas chromatography-mass spectrometry and analysis of enantiomers by capillary electrophoresis. J Anal Toxicol (2002) 1.01
Phenomenon of new drugs on the Internet: the case of ketamine derivative methoxetamine. Hum Psychopharmacol (2012) 1.01
Assessment of the neuropeptide S system in anxiety disorders. Biol Psychiatry (2010) 0.99
Human papillomavirus is not associated with colorectal cancer in a large international study. Cancer Causes Control (2010) 0.98
Polymorphisms within inflammatory genes and colorectal cancer. J Negat Results Biomed (2006) 0.98
Nanofluidic digital PCR for KRAS mutation detection and quantification in gastrointestinal cancer. Clin Chem (2012) 0.98
Relative abuse liability of gamma-hydroxybutyric acid, flunitrazepam, and ethanol in club drug users. J Clin Psychopharmacol (2007) 0.97
Efficacy of psychostimulant drugs for amphetamine abuse or dependence. Cochrane Database Syst Rev (2013) 0.94
Pharmacological interaction between 3,4-methylenedioxymethamphetamine (ecstasy) and paroxetine: pharmacological effects and pharmacokinetics. J Pharmacol Exp Ther (2007) 0.94
Interleukin-4 and interleukin-4 receptor polymorphisms and colorectal cancer risk. Eur J Cancer (2007) 0.94
MDMA (ecstasy) pharmacokinetics in a CYP2D6 poor metaboliser and in nine CYP2D6 extensive metabolisers. Eur J Clin Pharmacol (2005) 0.94
Thymoma and thymic carcinoma in the target therapies era. Cancer Treat Rev (2012) 0.94
Case-control study for colorectal cancer genetic susceptibility in EPICOLON: previously identified variants and mucins. BMC Cancer (2011) 0.93
Psychiatric, behavioural and social risk factors for HIV infection among female drug users. AIDS Behav (2011) 0.93
Caspase-3 activity, response to chemotherapy and clinical outcome in patients with colon cancer. Int J Colorectal Dis (2007) 0.92
Drugs on the web; the Psychonaut 2002 EU project. Prog Neuropsychopharmacol Biol Psychiatry (2006) 0.92
The consequences of 3,4-methylenedioxymethamphetamine induced CYP2D6 inhibition in humans. J Clin Psychopharmacol (2008) 0.92
Hypermethylation of the prostacyclin synthase (PTGIS) promoter is a frequent event in colorectal cancer and associated with aneuploidy. Oncogene (2005) 0.91
Polymorphisms of the dopamine receptor gene DRD2 and colorectal cancer risk. Cancer Epidemiol Biomarkers Prev (2005) 0.90
Functional alteration in frontolimbic systems relevant to moral judgment in cocaine-dependent subjects. Addict Biol (2012) 0.90
Idebenone treatment in paediatric and adult patients with Friedreich ataxia: long-term follow-up. Eur J Paediatr Neurol (2008) 0.90
Intrinsic cancer subtypes--next steps into personalized medicine. Cell Oncol (Dordr) (2015) 0.90
Cofactors associated with liver disease mortality in an HBsAg-positive Mediterranean cohort: 20 years of follow-up. Int J Cancer (2006) 0.89
Novel methylation panel for the early detection of neoplasia in high-risk ulcerative colitis and Crohn's colitis patients. Inflamm Bowel Dis (2013) 0.88
Genetic pathways and genome-wide determinants of clinical outcome in colorectal cancer. Cancer Res (2003) 0.88
Psychiatric comorbidity in young cocaine users: induced versus independent disorders. Addiction (2008) 0.87
Evaluation of plasma-free endocannabinoids and their congeners in abstinent cocaine addicts seeking outpatient treatment: impact of psychiatric co-morbidity. Addict Biol (2013) 0.86
Changes in CYP1A2 activity in humans after 3,4-methylenedioxymethamphetamine (MDMA, ecstasy) administration using caffeine as a probe drug. Drug Metab Pharmacokinet (2012) 0.86
BMP2/BMP4 colorectal cancer susceptibility loci in northern and southern European populations. Carcinogenesis (2012) 0.86
Colorectal cancer risk and the APC D1822V variant. Int J Cancer (2004) 0.85
The influence of genetic and environmental factors among MDMA users in cognitive performance. PLoS One (2011) 0.85
Organochlorine exposure and colorectal cancer risk. Environ Health Perspect (2004) 0.85
Polymorphisms in sulfotransferases SULT1A1 and SULT1A2 are not related to colorectal cancer. Int J Cancer (2005) 0.84
Staff regard towards working with substance users: a European multi-centre study. Addiction (2011) 0.84
Impact of co-occurring psychiatric disorders on retention in a methadone maintenance program: an 18-month follow-up study. Int J Environ Res Public Health (2009) 0.84
Tetrahydrobiopterin responsiveness in patients with phenylketonuria. Clin Biochem (2004) 0.83
Clinical pharmacology of 3,4-methylenedioxymethamphetamine (MDMA, "ecstasy"): the influence of gender and genetics (CYP2D6, COMT, 5-HTT). PLoS One (2012) 0.83
Semiparametric Bayesian modeling of random genetic effects in family-based association studies. Stat Med (2009) 0.83